Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Kiniksa Pharmaceuticals Ltd Market Cap
The Kiniksa Pharmaceuticals Ltd (KNSA) share price is expected to increase by 68.15% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered KNSA. Price targets range from $32 at the low end to $40 at the high end. The current analyst consensus for KNSA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assigned KNSA 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Kiniksa Pharmaceuticals Ltd to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KNSA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of KNSA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anupam Rama JP Morgan | Overweight | $40 | Maintains | Nov 5, 2024 |
| Liisa Bayko Evercore ISI Group | Outperform | $35 | Maintains | Oct 30, 2024 |
| Roger Song Jefferies | Buy | $40 | Initiates | Sep 13, 2024 |
| David Nierengarten Wedbush | Outperform | $34 | Maintains | Jul 23, 2024 |
| Eva Fortea Verdejo Wells Fargo | Overweight | $34 | Initiates | May 3, 2024 |
| Anupam Rama JP Morgan | Overweight | $30 | Maintains | May 1, 2024 |
| Liisa Bayko Evercore ISI Group | Outperform | $30 | Maintains | Apr 24, 2024 |
| David Nierengarten Wedbush | Outperform | $25 | Maintains | Jan 2, 2024 |
| Paul Choi Goldman Sachs | Buy | $32 | Maintains | Jul 26, 2023 |
| Anupam Rama JP Morgan | Overweight | $20 | Maintains | Mar 9, 2023 |
| Geoff Meacham B of A Securities | Buy | $34 | Maintains | Dec 29, 2021 |
B of A Securities | Buy | Initiates | Apr 1, 2020 | |
JP Morgan | Overweight | $24 | Maintains | Mar 11, 2020 |
Goldman Sachs | Buy | $18 | Upgrade | Dec 6, 2019 |
JMP Securities | Market Outperform | $35 | Maintains | Aug 14, 2019 |
Barclays | Overweight | Initiates | Mar 11, 2019 | |
Wedbush | Outperform | $33 | Reiterates | Dec 12, 2018 |
| Liisa Bayko JMP Securities | Market Outperform | $44 | Maintains | Sep 17, 2018 |
JP Morgan | Overweight | Initiates | Jun 18, 2018 | |
Goldman Sachs | Neutral | Initiates | Jun 18, 2018 |
When did it IPO
2018
Staff Count
297
Country
United Kingdom
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Sanj K. Patel
Market Cap
$1.55B
In 2023, KNSA generated $270.3M in revenue, which was a increase of 22.74% from the previous year. This can be seen as a signal that KNSA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kiniksa Pharmaceuticals (Nasdaq: KNSA) will participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 3, 2024, at 9:35 a.m. ET.
Why It Matters - Kiniksa Pharmaceuticals' participation in a major health conference could indicate upcoming developments or insights, potentially influencing stock performance and investor sentiment.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kiniksa Pharmaceuticals will participate in a fireside chat at the Jefferies London Healthcare Conference on November 19, 2024, at 12:00 p.m. GMT.
Why It Matters - Kiniksa's participation in a notable healthcare conference can signal potential strategic insights and updates, influencing investor sentiment and stock performance.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Kiniksa Pharmaceuticals will hold its Q3 2024 Earnings Conference Call on October 29, 2024, at 8:30 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters - Kiniksa Pharmaceuticals' Q3 earnings call will provide insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kiniksa's ARCALYST reported Q3 2024 net revenue of $112.2M, up 73% YoY. Full-year revenue outlook raised to $410-420M. The company maintains an annual cash flow positive expectation.
Why It Matters - Strong revenue growth for ARCALYST indicates increasing market demand, boosting investor confidence. Positive cash flow projections enhance financial stability, making the company an attractive investment.
Tue, 29 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Kiniksa Pharmaceuticals reported a quarterly loss of $0.18 per share, missing the Zacks Consensus Estimate of a loss of $0.01.
Why It Matters - Kiniksa's larger-than-expected quarterly loss signals potential operational challenges, which may lead to decreased investor confidence and impact stock performance.
Tue, 22 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kiniksa Pharmaceuticals will hold a conference call on October 29, 2024, at 8:30 a.m. ET to discuss Q3 2024 financial results and portfolio updates.
Why It Matters - Kiniksa Pharmaceuticals' upcoming conference call on Q3 results may signal updates on financial health and strategic initiatives, influencing stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
